Giovanna Cassone Salata

Mrs. Giovanna Cassone Salata

Universidade de São Paulo, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
GMGabriela Mojeiko
Gabriela Mojeiko
MBMoacir de Brito
Moacir de Brito
GSGiovanna Cassone Salata
Giovanna Cassone Salata
LLLuciana Lopes
Luciana Lopes

1 January 2018 in Drug Delivery
Verified
Journal Article
Open access
AMAmanda Migotto
Amanda Migotto
VCVanessa F. M. Carvalho
Vanessa F. M. Carvalho
GSGiovanna Cassone Salata
Giovanna Cassone Salata
FSFernanda W. M. da Silva
Fernanda W. M. da Silva
CYChao Yun Irene Yan
Chao Yun Irene Yan
LLLuciana Lopes
Luciana Lopes
Considering that breast cancer usually begins in the lining of the ducts, local drug administration into the ducts could target cancers and pre-tumor lesions locally while reducing systemic adverse effects. In this study, a cationic bioadhesive nanoemulsion was developed for intraductal administration of C6 ceramide, a sphingolipid that mediates apoptotic and non-apoptotic cell death. Bioadhesive properties were obtained by surface modification with chitosan. The optimized nanoemulsion displayed size of 46.3 nm and positive charge, properties that were not affected by ceramide encapsulation (0.4%, w/w). C6 ceramide concentration necessary to reduce MCF-7 cells viability to 50% (EC50) decreased by 4.5-fold with its nanoencapsulation compared to its solution; a further decrease (2.6-fold) was observed when tributyrin (a pro-drug of butyric acid) was part of the oil phase of the nanocarrier, a phenomenon attributed to synergism. The unloaded nanocarrier was considered safe, as indicated by a score <0.1 in HET-CAM models, by the high survival rates of Galleria mellonella larvae exposed to concentrations ≤500 mg/mL, and absence of histological changes when intraductally administered in rats. Intraductal administration of the nanoemulsion prolonged drug localization for more than 120 h in the mammary tissue compared to its solution. These results support the advantage of the optimized nanoemulsion to enable mammary tissue localization of C6 ceramide.

1 July 2021 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SCSandra Costa-Fernandez
Sandra Costa-Fernandez
JMJenyffer K.R. Matos
Jenyffer K.R. Matos
GSGaby S. Scheunemann
Gaby S. Scheunemann
GSGiovanna Cassone Salata
Giovanna Cassone Salata
MCMarlus Chorilli
Marlus Chorilli
LLLuciana Lopes
Luciana Lopes

1 August 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
VCVanessa F.M. Carvalho
Vanessa F.M. Carvalho
GSGiovanna Cassone Salata
Giovanna Cassone Salata
JMJenyffer K.R. de Matos
Jenyffer K.R. de Matos
SCSandra Costa-Fernandez
Sandra Costa-Fernandez
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
LLLuciana Lopes
Luciana Lopes

10 January 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
FBFernanda Walt Mendes da Silva de Bastiani
Fernanda Walt Mendes da Silva de Bastiani
CSCristina Spadari
Cristina Spadari
JMJenyffer Kelly Rocha de Matos
Jenyffer Kelly Rocha de Matos
GSGiovanna Cassone Salata
Giovanna Cassone Salata
LLLuciana Biagini Lopes
Luciana Biagini Lopes
KIKelly Ishida
Kelly Ishida
Topical drug administration is frequently used for the treatment of vaginal candidiasis; however, most formulations using this route do not provide prolonged drug release. Our aim was to evaluate the antifungal efficacy of amphotericin B (AMB) and miltefosine (MFS) incorporated in nanocarriers for sustained drug release, in a murine model of vaginal candidiasis. AMB and MFS were incorporated in different topical formulations, namely: conventional vaginal cream (daily dose for 6 days; MFS-CR and AMB-CR groups), microemulsion that transforms into a liquid crystalline gel in situ (single dose, or in 3 doses, every 48 h; AMB-ME and MFS-ME groups) and alginate nanoparticles (single dose; MFS-AN group). Formulations were administered intravaginally in BALB/c female mice 24 h post-infection by Candida albicans yeasts. On the 7th day post-infection the animals were euthanized for mycological and histological analyses. Formulation persistence in the vaginal canal was assessed for 7 days by in vivo imaging, using nanocarriers labeled with Alexa-Fluor 647. AMB-ME(3x), MFS-ME(3x) and MFS-AN(1x) formulations were able to control fungal infection at comparable levels to those vaginal cream formulations. Notably, a single dose of MFS-AN was sufficient to reduce the fungal burden as effectively as MFS-ME(3x) and MFS-CR(6x). In vivo imaging showed that nanocarriers allowed prolonged antifungal activity by intravaginal administration reducing drug administration frequency. Therefore, AMB and MFS incorporated into a microemulsion and MFS encapsulated in alginate nanoparticles could be effective therapeutic alternatives for vaginal candidiasis, likely due to the sustained antifungal activity provided by these nanocarriers.

1 September 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MGMaria Teresa Junqueira Garcia
Maria Teresa Junqueira Garcia
TGThalita Pedralino Gonçalves
Thalita Pedralino Gonçalves
ÉMÉricka São Félix Martins
Éricka São Félix Martins
TMTereza Silva Martins
Tereza Silva Martins
MFMarcia C Carvalho de Abreu FANTINI
Marcia C Carvalho de Abreu FANTINI
LLLuciana Lopes
Luciana Lopes